Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSC-200-A0201 + TSC-201-B0702
- Development stage
- Unknown
- Lead developer
- TCRx Therapeutics
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TSC-200-A0201 + TSC-201-B0702 is a combination of two autologous, engineered TCR-T cell therapies developed by TScan Therapeutics for the treatment of solid tumors. Each product targets a specific tumor-associated antigen presented on defined HLA types. TSC-200-A0201 targets HPV16 antigens in the context of HLA-A*02:01, while TSC-201-B0702 targets MAGE family member C2 antigens in the context of HLA-B*07:02. Both are designed to recognize and eliminate cancer cells expressing these antigens, aiming to overcome tumor heterogeneity and reduce relapse risk by multiplexing different antigen-HLA specificities within a single patient. The combination is being evaluated in Phase 1 clinical trials for multiple HPV-related cancers and other solid tumors[1][3][4][5][6].
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on TSC-200-A0201 + TSC-201-B0702.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSC-200-A0201 + TSC-201-B0702.